sTNF-RISoluble Tumor Necrosis Factor Receptor I
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
In the present study, we measured the serum levels of 10 proinflammatory cytokines (IL-1[beta], IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-22, IL-23, sTNF-RI, and sTNF-RII), as well as CRP levels and the ESR, in patients with HS and healthy controls.
IL, interleukin; CRP, sTNF-RI, soluble TNF receptor I; sTNF-RII, soluble TNF receptor II; C-reactive protein; ESR, level erythrocyte sedimentation rate; HC, healthy controls; LIA, low inflammatory activity; MIA, moderate inflammatory activity; HIA, high inflammatory activity.
Bu gali mada ARA tamp olgularda, iki antiinflamatuvar sitokin olan interlokin-I reseptor antagonist (IL-IRa) ve solubl tumor nekrosis faktor reseptor I sTNF-RI) duzeyleri tam aninda ve tedavi baslandiktan 3 ay sonra olculerek hastaligin degisik evrelerindeki sitokin konsantrasyonlarmdaki degisikligin saptanmasi amaclanmistir.
Yontemler: Serum IL-IRa ve sTNF-RI duzeyleri ARA tamp olgularda tam aninda (n=21) ve tedavi basladiktan 3 ay sonra (n=15) degerlendirilmistir.
Bulgular: Serum IL-1 Ra ve sTNF-RI duzeyleri ARA tanili olgularda hem akut donemde hem de remisyonda yas uyumlu saglikli kontrol grubuna gore anlamli yuksek bulunmustur (p=0.001 ve p=0.0001).
As a continuum of our previous studies, serum concentrations of two anti-inflammatory cytokines, IL-IRa and human soluble tumor necrosis factor receptor I (sTNF-RI) were determined in patients with ARF at the time of admission and 3 months after treatment in order to evaluate changes in cytokine concentrations occurring during different stages of the disease.
Serum sTNF-RI, IL-I Ra concentrations were measured from blood samples taken on admission before beginning any medication (Group Ia, n=21) and at the end of the following 3 months under treatment (Group Ib, n=15).
The sTNF-RI, sIL-IRa were measured quantitatively in serum using enzyme-linked immunosorbent assay (ELISA) with commercially available kits (Biosource, Nivelles, Belgium).
Serum levels of sTNF-RI and sIL-IRa were significantly different between groups Ia, Ib and controls (p=0.001 and p=0.0001, respectively) (Table 2).
In our study, sTNF-RI levels were found to be significantly higher in the peripheral blood of ARF patients on admission and after receiving adequate therapy when compared to healthy controls.
No significant difference was observed in sTNF-RI and IL-1Ra levels between these two patient groups.
Significantly elevated levels of antiinflammatory cytokines sTNF-RI and IL-1Ra in respect to controls were important showing the inflammatory process going on in these patients both in acute and remission states, although tending to decrease in remission.